

REQUEST FOR QUOTATION No. 16 12 2025 T

In connection with the implementation of project entitled “**ADCraft – next-generation small molecule payloads for Antibody-Drug Conjugates in oncology**” (Grant Agreement No. KPOD.07.07-IW.07-0277/24), co-funded from the call FOR ENTERPRISES TO IMPLEMENT RESEARCH IN THE AREA OF MEDICINE SAFETY, INNOVATIVE THERAPIES AND MEDICINES OF THE FUTURE No. 2024/ABM/05/KPO, organized by the Medical Research Agency (ABM) as part of the National Plan for Rehabilitation and Enhancement of Immunity, Component D: Efficiency, Accessibility and Quality of the Health Care System, Investment D3. 1.1 Comprehensive development of research in medical and health sciences and in connection with the obligation to make purchases based on the most economically advantageous offer while adhering to the principles of fair competition, efficiency, openness, and transparency, Ryvu Therapeutics S.A. hereby submits the inquiry regarding the provision of the following service: **the Efficacy and PK/PD studies in BRE cancer CDX model**.

I. ORDERING PARTY:

Ryvu Therapeutics S.A.,

Sternbacha 2, 30-394 Krakow, Poland

EU VAT: 679-29-42-955, REGON: 120515330, KRS: 000367359

in the further content of the RFQ, hereinafter referred to as the "Ordering Party", "Sponsor" or "Ryvu".

II. DESCRIPTION OF THE SUBJECT MATTER OF THE CONTRACT:

II.1. SUBJECT MATTER OF THE CONTRACT

Part of the order: Part 1 - the Efficacy and PK/PD studies in BRE cancer CDX model.

CPV name and code: 73110000-6 Research services.

Cell lines and animals

The costs of *in vivo* studies after subcutaneous inoculation of **NCI-N87** cells into female immunodeficient mice (preferentially nude mice), age-matched, will be provided by the Contractor. Cells will be cultured by the Contractor before inoculation.

1. PK/PD experiment in immunodeficient mice

1.1 Inoculation of the cells and randomization

Cells will be inoculated subcutaneously into one flank of the mouse. Randomization of animals to experimental groups will be performed once the average tumor volume reaches ~150 mm³.

1.2 Compounds and ADC administration

The ADCs from group 5-7 will be provided by the Sponsor. Reference compound and antibody should be provided by the Contractor. Compound, ADC, antibody and vehicles will be administered intravenously (IV), twice weekly (BIW), for about 3 weeks. Option: once weekly (QW) dosing for about 3 weeks. The provisional plan of the experiment is presented in **Table 1**.

Table 1. The general plan of the efficacy experiment:

Group	Compound	Dose mg/kg	Route	Schedule	Cell-line	Inoculation	Gender	Animal Number*
1	Vehicle 1	-	IV	BIW or QW	NCI-N87	SC	F	12
2	Ref compound 1	Tbd	IV	BIW or QW	NCI-N87	SC	F	12
3	Vehicle 2	Tbd	IV	BIW or QW	NCI-N87	SC	F	12
4	Antibody	Tbd	IV	BIW or QW	NCI-N87	SC	F	12
5	Isotype ADC	-	IV	BIW or QW	NCI-N87	SC	F	12
6	ADC 1	Tbd	IV	BIW or QW	NCI-N87	SC	F	12
7	ADC 1	Tbd	IV	BIW or QW	NCI-N87	SC	F	12

Legend: IV – intra venous; QW– once weekly, BIW – twice a week; SC – subcutaneously

F – female; *animal number per group after randomization.

1.3 Evaluated parameters

Clinical signs will be checked daily, body weight will be checked 2-3 times per week, and tumor volume will be measured two times per week. The Contractor should inform about the availability of the data during the study course and about the frequency of updates.

1.4 Sample collection

Survival blood sampling (for plasma preparation) within working hours from 6 mice/group will be performed after dose 1 (3 mice/group at 1h and 1 day; 3 mice/group at 3 days and 6 days) and dose 6 (3 mice/group at 1h and 1 day; 3 mice/group at 3 days and 6 days). Tumor sampling will be done within working hours from the remaining 6 mice/group at 48h after dose 1 (3 mice/group) and dose 3 (3 mice/group). Additionally, tumor sampling will be done at 48h after dose 6 (3 mice/group with survival blood sampling at 1h and day 1). Plasma leftovers and tumors will be frozen and sent to the Sponsor.

Option (QW): Survival blood sampling (for plasma preparation) within working hours from 6 mice/group will be performed after dose 1 and dose 3 (3 mice/group at 1h and 1 day; 3 mice/group at 3 days and 6 days). Tumor sampling will be done within working hours from the remaining 6 mice/group at 48h after dose 1 (3 mice/group) and dose 2 (3 mice/group). Additionally, tumor sampling will be done at 48h after dose 3 (3 mice/group with survival blood sampling at 1h and day 1). Plasma and tumors will be frozen and sent to the Sponsor.

1.5 Shipment

Samples will be stored at -80°C until shipment on dry ice to Sponsor, which must be organized as soon as possible after the experiment (within 5 working days after study completion). Shipment costs to Poland should be included in the quotation.

1.7 Report

Non-GLP study and report.

2. Efficacy study in immunodeficient mice

2.1 Inoculation of the cells and randomization

Cells will be inoculated subcutaneously into one flank of the mouse. Randomization of animals to experimental groups will be performed once the average tumor volume reaches ~100 mm³.

2.2 Compounds and ADC administration

The ADCs from group 7 -10 will be provided by the Sponsor together with formulation instructions. Reference compound, antibody and ADC should be provided by the Contractor. Compound, ADC, antibody and vehicles will be administered intravenously (IV), twice (BIW) weekly, for maximum 4 weeks. Option: once weekly (QW) dosing for maximum 4 weeks. The provisional plan of the experiment is presented in **Table 2**.

Table 2. The general plan of the PK/PD experiment:

Group	Compound	Dose mg/kg	Route	Schedule	Cell-line	Inoculation	Gender	Animal Number*
1	Vehicle 1	-	IV	BIW or QW	NCI-N87	SC	F	10
2	Ref ADC	Tbd	IV	BIW or QW	NCI-N87	SC	F	10
3	Vehicle 2	-	IV	BIW or QW	NCI-N87	SC	F	10
4	Ref Compound	Tbd	IV	BIW or QW	NCI-N87	SC	F	10
5	Vehicle 3	-	IV	BIW or QW	NCI-N87	SC	F	10
6	Antibody	Tbd	IV	BIW or QW	NCI-N87	SC	F	10
7	Iso ADC	Tbd	IV	BIW or QW	NCI-N87	SC	F	10
8	ADC 1	Tbd	IV	BIW or QW	NCI-N87	SC	F	10
9	ADC 1	Tbd	IV	BIW or QW	NCI-N87	SC	F	10
10	ADC 1	Tbd	IV	BIW or QW	NCI-N87	SC	F	10

Legend: IV – intra venous; QW– once weekly, BIW – twice a week; SC – subcutaneously

F – female; *animal number per group after randomization.

2.3 Evaluated parameters

Clinical signs will be checked daily starting from the treatment commencement, body weight will be checked 2-3 times per week, and tumor volume will be measured two times per week. The contractor should inform about the availability of the data during the study course and about the frequency of updates.

OPTION (Efficacy follow-up): The Sponsor anticipates the possibility of observing the tumors and body weight after completion of administration, approximately 2 weeks.

2.4 Sample collection

Terminal blood (plasma preparation) and tumor sampling in one timepoint (48h) after last dose (within working hours). Plasma and tumors will be frozen and sent to the Sponsor.

2.6. Shipment

Samples will be stored at -80°C until shipment on dry ice to Sponsor, which must be organized as soon as possible after the experiment (within 5 working days after study completion). Shipment costs to Poland should be included in the quotation.

2.6 Report

Non-GLP study and report.

- Contract volume:
 - Minimum contract volume:
 - 0 PK/PD experiment in immunodeficient mice,
 - 0 efficacy study in immunodeficient mice study.
 - Maximum contract volume:
 - Up to 2 PK/PD experiment in immunodeficient mice,
 - Up to 2 efficacy study in immunodeficient mice study.
- The Ordering Party does not guarantee commissioning a minimum number of studies. The execution of individual studies will depend on the actual needs of the Ordering Party.
- The study may be performed either BIW (twice-weekly) or QW (once-weekly), depending on the Ordering Party's requirements.
- Orders will be placed in parts, in the form of Purchase Orders issued throughout the duration of the contract.
- The Ordering Party does not allow the possibility of submitting partial offers (1 part of the subject of the contract). Partial offers are not allowed because the contract involves interdependent studies that must be executed as a single, coherent scope to ensure consistency and reliability of results.
- The Ordering Party does not allow the possibility of submitting variant offers

II.2. CONTRACT PERFORMANCE PRINCIPLES:

- **PAYMENT TERMS:** payment period for invoices of not less than **30 calendar days**.
The payment period is an admission condition, offers indicating a shorter payment deadline will be rejected.
- **TURNAROUND TIME:** by the end of **Q1 2026**.
Turnaround time is an admission condition, offers indicating a longer completion deadline will be rejected.
- **CONTRACT TERM:** The deadline for completion of the contract is **31 March 2026**.
In the event of an extension of the Project completion date, the contract may be prolonged in accordance with changes to the Project's co-financing agreement.
- **SHIPMENT OF SAMPLES AFTER EXPERIMENT COMPLETION:** within 5 working days after study completion.
This period covers the preparation of all samples, their proper storage and the arrangement and dispatch of the shipment to the Ordering Party, including obtaining a tracking number.

III. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS:

The assessment of the conditions for participation in the procedure will be conducted on a “meets/does not meet” basis. The contract may be awarded to Bidders who meet all of the following conditions:

1. Experience with Tumor Model and Operational Capacity - The Bidder must demonstrate that it has the experience and operational capacity necessary to properly perform the subject of the contract, including:
 - a. Experience with relevant tumor model - experience in working with NCI-N87 tumor model,

- demonstrated by providing historical results on tumor growth kinetics of the NCI-N87 cell line (preferentially in female nude mice); and
 - b. Operational capacity – the ability to conduct PK/PD studies and efficacy studies in parallel.
- Assessment Method:
 - Point (a): Based on the submitted historical data.
 - Point (b): Based on the statement included in the offer form.
- Required Documents:
 - Historical results on tumor growth kinetics of the NCI-N87 cell line (preferentially in female nude mice);
 - Bidder's statement confirming the capacity to conduct PK/PD and efficacy studies in parallel, included in the offer form.
- 2. Country of Establishment and Place of Performance - Bidders must have their registered office or place of business, and declare that the contract will be executed, in:
 - a. a Member State of the European Union, or
 - b. a country that is a party to an international agreement currently in force with the European Union concerning public procurement, such as: the Agreement on Government Procurement (GPA), the Trade and Cooperation Agreement (TCA), the Comprehensive Economic and Trade Agreement (CETA), the Free Trade Agreement between the EU and the countries of the European Free Trade Association (EFTA), other applicable international agreements on public procurement concluded by the European Union.
 - Assessment Method: Based on the statement in the offer form.
 - Required Documents: A Bidder's statement confirming compliance with both the country of establishment and place of performance, included in the offer form.
- 3. No Grounds for Exclusion under National Security Regulations - Bidders must not be subject to exclusion pursuant to Article 7(1) of the Act of 13 April 2022 on special solutions for counteracting support for aggression against Ukraine and serving the protection of national security (Journal of Laws, item 835).
 - Assessment Method: Based on the statement in the offer form.
 - Required Documents: Bidder's statement confirming compliance, included in the offer form.
- 4. No Conflict of Interest - Due to the prohibition of conflict of interest, Bidders who are personally or financially related to the Ordering Party will be excluded from applying for the award of a contract. Capital or personal ties shall be understood as mutual relations between the Ordering Party or persons authorized to incur obligations on behalf of the Ordering Party or persons performing activities on behalf of the Ordering Party related to the preparation and conduct of the procedure for selecting the Contractor and the Contractor, consisting in particular in:
 - participation in the company as a partner in a civil law partnership or partnership, holding at least 10% of shares (unless a lower threshold results from applicable law), serving as a member of a supervisory or management body, proxy, or representative;
 - being married, related by blood or marriage in the direct line, related in the collateral line up to the second degree, or connected through adoption, guardianship, or cohabitation with the contractor, its legal representative, or members of the contractor's management or supervisory bodies;
 - remaining in such a legal or factual relationship with the contractor that may raise justified doubts as to their impartiality or independence in connection with the procurement procedure.
 - Assessment Method: Based on the statement in the offer form.
 - Required Documents: A bidder's statement confirming compliance, included in the offer form.

The Ordering Party reserves the right to request additional information or clarifications from Bidders regarding submitted statements and historical data, in order to verify compliance with the participation conditions.

IV. EVALUATION OF OFFERS:

IV.1. The evaluation of offers will consist of three stages:

- A. Formal assessment – verification of compliance with the conditions for participation in the proceedings set out in Section III and mandatory conditions set out in Section II.2.
- B. Substantive assessment – assessment of the compliance of the offer with the description of the subject of the contract indicated in point II.1.,
- C. Scoring – carried out on the basis of the criteria for evaluating offers indicated in point IV.2. of this inquiry.

IV.2. CRITERIA FOR THE EVALUATION OF TENDERS

Criterion: **Net price ("C") – weight: 100% (10,00 points)**

1. The Net Price subject to evaluation is the total offer price, calculated as the sum of the unit prices submitted by the Bidder multiplied by the maximum contract volume, as specified below:
 - PK/PD experiments in immunodeficient mice: up to 2 studies,
 - Efficacy studies in immunodeficient mice: up to 2 studies.
 Calculation formula: (BIW Unit Price for PK/PD × 2) + (BIW Unit Price for Efficacy × 2).
 For evaluation purposes, the Unit Price corresponding to the twice-weekly dosing schedule (BIW) will be used.
 If the price is expressed as a range, the higher value will be used for evaluation purposes.
 The offered price must include all costs associated with the service, including shipment to Poland.
2. In the case of prices given in foreign currencies, in order to compare offers, they will be converted into PLN at the average exchange rate of the National Bank of Poland in force on the day of closing the proceedings indicated in point V.1.
3. In the Net Price criterion, points will be awarded (to two decimal places) according to the formula:

$$\text{Criterion 'C'} = \frac{\text{the lowest net price offer among the offers submitted}}{\text{net price of the examined offer}} \times 10,00 \text{ points}$$

4. The Ordering Party will choose the offer that obtains the highest number of points as the most advantageous.
5. The contract is awarded on the basis that supplementary orders may be placed.
6. If the Ordering Party must choose between at least two offers with an equal number of points, the Ordering Party will select the offer that is more advantageous in terms of environmental and climate impact. To assess this, Bidders will be asked the question: *"Do you use the ISO 14001 Environmental Management System or EMAS? (YES/NO)"*.
 The selection will be based on the answer provided. If no response is given, the Ordering Party will assume that the Bidder does not use any Environmental Management System.
 If this criterion is still insufficient to make a decision, the Ordering Party will invite the Bidders who submitted equally evaluated offers to submit additional offers within a specified period. The additional offers may not be less advantageous than the originally submitted offers in any evaluation criterion.
7. If the offered, total net price differs by more than 30% from the arithmetic mean of the prices of all submitted valid offers not subject to rejection or raises doubts of the Ordering Party as to the possibility of performing the subject of the contract in accordance with the requirements specified in the request for proposal or resulting from separate regulations, the Ordering Party will require the Bidder to submit explanations within the prescribed period, including the submission of evidence regarding the calculation of the price or cost. The Ordering Party will evaluate these explanations in consultation with the Bidder and may reject this offer if the explanations submitted together with the evidence do not justify the price or cost of the offer submitted.

V. PLACE, DATE AND PROCEDURE FOR SUBMISSION OF TENDERS:

- V.1. **The offer must be submitted via the [BK2021](#) website no later than 23rd December 2025 at 23:59 CET.**
- V.2. The offer together with attachments should be made in Polish or English.
- V.3. The offer should be prepared in accordance with the form constituting Appendix 01 to this RFQ.
- V.4. Timely submission of an offer is determined by the date of submission of the offer via the BK2021.
- V.5. All costs related to the preparation and submission of the offer shall be borne by the Bidder.
- V.6. Submission of the offer constitutes unconditional acceptance of the terms and conditions of this RFQ, including all attachments.
- V.7. The offer must be signed by persons authorized to represent the Bidder, in accordance with the registration documents or a valid power of attorney. Electronic signatures are accepted, including qualified electronic signatures, DocuSign, AdobeSign, as well as trusted signatures (trusted profile) or scanned handwritten signatures.
- V.8. In the course of comparing and evaluating tenders, the Ordering Party shall correct obvious clerical and accounting errors in the tenders, at the same time informing the Bidder about the content of the amendment. If the Bidder does not agree to correct the errors within the time limit indicated by the Ordering Party, its offer shall be rejected.
- V.9. The part of the offer that contains information constituting a trade secret within the meaning of the provisions on combating unfair competition, and the Contractor reserves their confidentiality, should be described as "Confidential". The Ordering Party shall not be liable for the disclosure of information constituting a trade secret provided to it by the Contractor contrary to the provisions of this subsection. A trade secret is understood as technical, technological, organizational information of the enterprise not disclosed to the public or other information of economic value for which the entrepreneur has taken the necessary measures to maintain their confidentiality, in accordance with the Act of 16 April 1993 on combating unfair competition (consolidated text: Journal of Laws of 2022, item 1233; binding text).

V.10. An offer that does not meet the requirements set out above shall be rejected, subject to the provisions on the possibility of allowing the Ordering Party to call on Bidders who have not submitted the required statements, or who have not submitted registration documents or powers of attorney, or who have submitted the above-mentioned statements and documents containing errors or incomplete or raising doubts indicated by the Ordering Party to their submission, supplementation or correction within the prescribed period, or to provide explanations, unless despite their submission the Bidder's offer would be rejected or the procedure would be subject to annulment. If the Bidder does not submit, supplement or correct the above-mentioned statements or documents within the time limit set by the Ordering Party, its offer shall be rejected. Subsequently, the committee will evaluate the offers in accordance with point IV.

VI. OFFER VALIDITY PERIOD:

The offer should include its validity period at least until **31st March 2026**.

VII. NOTICE OF SELECTION

Information on the selection of the best offer will be published on the BK2021 website. This information will include names of bidders, their registered offices and the evaluated net price. By participating in the proceedings, the bidder agrees to the publication of this information.

VIII. ESSENTIAL PROVISIONS OF THE AGREEMENT:

- IX.1. The successful Bidder will be obliged to conclude the contract on the terms and conditions set out in this RFQ and Offer.
- IX.2. If the selected Bidder withdraws from the conclusion of the contract with the Ordering Party, the Ordering Party may conclude a contract with the next contractor whose offer will obtain the next highest number of points.
- IX.3. The contract concluded as a result of these proceedings shall be amended if any of the following circumstances occur:
 - a. In the event of a change in applicable laws or regulations, where it is necessary to align the provisions of the agreement with the current legal framework (including applicable standards);
 - b. Where the need for amendment results from updates to guidelines, recommendations, or decisions issued by the institution providing funding for the agreement;
 - c. With respect to the term of the agreement - if changes arise from amendments to the co-financing agreement for the Project, including extensions of the overall Project duration or specific Project stages;
 - d. When the amendment concerns the provision of additional services not included in the original agreement (supplementary orders), provided that the value of such amendments does not exceed 50% of the original agreement value.
- IX.4. The Ordering Party reserves the right to impose contractual penalties on the Contractor in the event of non-performance, improper performance, or delay in fulfilling obligations under the contract.
The Contractor shall pay the contractual penalties on time and to the account specified by the Ordering Party. In the event of non-payment, the Ordering Party has the right to deduct contractual penalties from the remuneration due to the Contractor, without the need to obtain the Contractor's consent.
In the event of damage exceeding the amount of contractual penalties stipulated in the Agreement, the Ordering Party may claim supplementary compensation on general terms.

ADDITIONAL INFORMATION:

- X.1. In the event of discrepancies between the provisions of the announcement on the BK2021 website and the records of the inquiry in the PDF version, the PDF version of the request for quotation attached to the announcement shall be binding.
- X.2. These proceedings are not subject to the provisions of the Public Procurement Law of 29 January 2004 (consolidated text as of 11 September 2019, Journal of Laws 2022, item 1710, as amended).
- X.3. These proceedings are conducted **in accordance with the principle of competitiveness**. These proceedings shall be conducted in accordance with the principles of fair competition, efficiency, publicity, transparency and equal access.
- X.4. The Bidder may ask the Ordering Party to clarify the content of the RFQ. If the request for clarification of the content of the RFQ was received later than by the end of **20th December 2025**, the Ordering Party may provide explanations or leave the request without consideration. Questions regarding the content of RFQ should be sent via the "Questions" tab.
- X.5. The Ordering Party shall make every effort to avoid a conflict of interest understood as a lack of impartiality and objectivity. Conflict of interest means any situation in which persons involved in the preparation or conduct of a

procurement procedure or likely to influence the outcome of that procedure have, directly or indirectly, a financial, economic or other personal interest which may be perceived to jeopardize their impartiality and independence in relation to the procurement procedure. In order to avoid a conflict of interest, the contract may not be awarded to entities related personally or financially to the Ordering Party.

- X.6. Whenever the Ordering Party uses trademarks / brands / standards / names of producers in the documentation, it should be assumed that the phrase "or equivalent" was used in relation to them, thus it is permissible to submit a offer in which an equivalent subject of the contract is indicated in relation to the one described by the Ordering Party. Indications in relation to the expected technical parameters, and indications for specific types and producer names are of a general nature, referring only to exemplary indications of equivalent products and are not the only acceptable solution. On this basis, the Ordering Party allows equivalent solutions. The Contractor who submits an equivalent offer is obliged to prove, under pain of rejection of the offer, that the submitted offer is equivalent to the one described by the Ordering Party.
- X.7. The Ordering Party reserves the right to change the content of the request for proposal, the changes made will be published in the BK2021, and the deadline for sending offers will be extended by the time necessary to introduce changes in offers, if it is necessary due to the scope of the introduced changes.
- X.8. The Ordering Party reserves the right to ask the Bidders at each stage of the evaluation of tenders for additional information, documents, additions or explanations. The Ordering Party shall contact the Bidder electronically (e-mail address) indicated in the content of the offer sent by the Bidder.
- X.9. Offers will be evaluated by a tender committee.
- X.10. Bidders are entitled to a legal remedy in the form of a protest regarding the evaluation of tenders.
- X.11. This request for quotation does not oblige the Ordering Party to conclude a contract.
- X.12. The Ordering Party reserves the right to close the proceedings without selecting any of the offers or to cancel the proceedings in the event of:
 - a. where no tenders have been received, or only those to be rejected have been received, or where all Bidders have been excluded from the procedure or have not fulfilled the conditions for eligibility or participation in the procedure;
 - b. when the price of the most advantageous offer exceeds the amount that the Ordering Party intends to spend on financing the contract;
 - c. occurrence of design changes or a significant change in circumstances causing that conducting the procedure or performing the contract is not in the interest of the Ordering Party;
 - d. the occurrence of an irremediable defect preventing the conclusion of the contract;
 - e. when the Contractor evades the conclusion of the contract,
 - f. in case of force majeure.

In the event of closing the proceedings without selecting the Contractor or cancelling the proceedings, the Ordering Party shall notify the Bidders who submitted offers and shall make public the relevant information together with the reason in the manner in which the request for proposal was made public.

IX. PERSONAL DATA PROTECTION:

- X.1. To implement this Agreement, the Parties, as independent controllers, shall communicate to each other personal data of their representatives or agents and of other persons as necessary according to request for quotation.
- X.2. The legal basis for the processing of the aforementioned data is the legitimate interest of each Party referred to in Article 6(1)(f) of the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons concerning the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (General Data Protection Regulation - hereinafter referred to as GDPR) related to the performance of the request for the quotation.
- X.3. The Bidder undertakes to inform the persons referred to in point 1 of the necessity of transferring their data to implement this request for quotation, including the purpose and scope of the transferred data. The Tenderer is also obliged to provide the persons with information on the processing of their data in accordance with GDPR by RYVU.

X. RYVU INFORMATION CLAUSE:

Information on the processing of personal data by RYVU:

- 1. The controller of personal data:
The controller of your personal data is Ryvu Therapeutics S.A. (hereinafter "we").
You can contact us in the following ways:
 - by post to the address: Sternbacha 2, 30-394 Krakow, Poland
 - by e-mail: gdpr@ryvu.com

2. Data protection officer (DPO):
We have appointed a data protection officer. This is the person you can contact for all matters concerning the processing of personal data and the exercise of your rights in relation to data processing. You can contact the DPO in the following ways:
 - by post to the address: Sternbacha 2, 30-394 Krakow, Poland
 - by e-mail: dpo@ryvu.com
3. Purposes of processing your personal data and legal basis for such processing:
We will process your personal data because you are a representative of the party submitting an offer or you are a contact person dedicated for us by our contractor.
Therefore, we will process your data for the following purposes:
 - In connection with the offer proceedings and potential conclusion of an agreement with the entity you represent (in the case of persons representing the client), as well as to contact you regarding ongoing business matters. The legal basis for data processing is our legitimate interest (Article 6(1)(f) GDPR) in being able to maintain ongoing contact with our contractors (i.e., their employees/collaborators).
4. Source of data:
We receive your data directly from you or from your employer/entity you represent.
From your employer/entity you represent we receive data such as your name, business telephone number and email address, place of work, job title, information on what type of matters you deal with.
5. Retention period of your personal data:
We will process your personal data during the request for quotation proceedings and until the expiration of claims arising from the request for quotation proceedings.
6. Recipients of your personal data:
We will transfer your personal data to our suppliers to whom we outsource personal data processing services, such as IT services. Such providers will process data based on a contract with us and only under our instructions.
7. Your rights concerning the processing of your personal data:
You have the following rights concerning the processing of your personal data:
 - the right to object to the processing of your data on grounds of your particular situation,
 - the right of access to your personal data,
 - the right to ask for rectification of your personal data,
 - the right to request the erasure of your personal data,
 - the right to request restrictions on the processing of your personal data.To exercise the above rights, please contact us (contact details above).
8. Right to object:
As we process your data based on our legitimate interest - you have the right to object to the processing on grounds of your particular situation.
9. Right to complain to the authority:
You also have the right to complain with the supervisory authority dealing with the protection of personal data, i.e. the President of the Office for Personal Data Protection.

ATTACHMENTS:

Appendix 01 – Offer form

BK2021 - Instructions for Foreign Bidders

Since the BK2021 platform is available only in Polish, we recommend using the browser's automatic translation feature. Below are links providing step-by-step instructions on how to register, submit offers, ask questions, and navigate the portal.

Official website: <https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>

Direct link to RFQ: <https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/ogloszenia/258185>

Useful links:

- Registration: [Help for Abroad Users – Registration](#)
- Submitting Offers: [Help for Abroad Users – Offers](#)
- Asking Questions: [Help for Abroad Users – Asking Questions](#)
- Website Navigation (Browser): [Help for Abroad Users – Browser](#)